Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes

  • By

  • Benoit Peyronnet

  • Benjamin M. Brucker

  • Cosimo De Nunzio

  • Christian Gratzke

  • John Heesakkers

  • Martin C. Michel

  • Maurizio Serati

  • David Staskin

  • Christopher Chapple

  • November 3, 2025

Share

  • 1

    The article is a correction to a previously published review on Vibegron for overactive bladder.

  • 2

    The correction addresses an error in the publication of Fig. 1 in the original article.

  • 3

    The correct figure is provided alongside the incorrect version for clarity.

  • 4

    The original article was published in the World Journal of Urology in 2025.

  • 5

    The DOI for the original article is 10.1007/s00345-025-05799-8.

Original Source(s)

Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes

  • by Benoit Peyronnet, Benjamin M. Brucker, Cosimo De Nunzio, Christian Gratzke, John Heesakkers, Martin C. Michel, Maurizio Serati, David Staskin, Christopher Chapple

  • November 3, 2025

Related Content

FDA Expands Bladder Cancer Regimen

KEYNOTE-B15/EV-304 demonstrated statistically significant improvements in event-free and overall survival with perioperative pembrolizumab plus enfortumab vedotin-ejfv compared with neoadjuvant gemcitabine plus cisplatin.

Assessment of the Accuracy and Trustworthiness of Kidney Stone Information on TikTok and Bilibili: A Cross-Sectional Analysis

3D holographic reconstruction and intraoperative navigation combined with CBL teaching in laparoscopic partial nephrectomy training for urology residents